Arch Biopartners (TSE:ARCH)

:ARCH

ARCH

Arch Biopartners

RESEARCH TOOLSreports

Want to see TSE:ARCH full AI Analyst Report?

Arch Biopartners (ARCH) Price & Analysis

46 Followers

ARCH Stock Chart & Stats

C$1.37

-C$0.06(-3.14%)

At close: Jan 08 4:00 PM EST

C$1.37

-C$0.06(-3.14%)

Day’s Range― - ―

52-Week RangeC$0.39 - C$1.95

Previous CloseN/A

Volume5.12K

Average Volume (3M)43.97K

Market Cap

C$30.23M

Enterprise ValueC$32.86M

Total Cash (Recent Filing)C$4.16K

Total Debt (Recent Filing)C$2.63M

Price to Earnings (P/E)―

Beta0.82

Next Earnings

Jun 02, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.04

Shares Outstanding67,933,290

10 Day Avg. Volume31,059

30 Day Avg. Volume43,967

Financial Highlights & Ratios

PEG Ratio0.88

Price to Book (P/B)-21.63

Price to Sales (P/S)0.00

P/FCF Ratio-53.01

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.16

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Platform & Antibody PipelineA platform that generates monoclonal antibody candidates supports a sustainable R&D engine and multiple follow-on assets. Platform-derived IP increases licensing appeal and strategic optionality, enabling partnerships or out-licensing that can fund development without immediate commercial sales.

Focus On High‑unmet-need IndicationsTargeting acute inflammation and ARDS addresses persistent, high-unmet clinical needs with durable demand and high potential value per approved therapy. These structural market dynamics attract partner interest and create long-term commercialization opportunities if clinical success is achieved.

Lean Operating StructureA very small headcount implies low fixed overhead and operational flexibility, stretching limited capital further. For a clinical-stage biotech, a lean structure can extend runway per financing, focus spend on development milestones, and improve capital efficiency until partnering or approval occurs.

Bears Say

No Product Revenue And Recurring SalesAbsence of product revenue means the company must rely on partnerships, milestone payments or financing to fund operations. Sustained losses increase the frequency and size of external capital raises, diluting equity and constraining long-term investment choices absent a definitive clinical or licensing event.

Negative Equity And Thin Asset BaseNegative shareholder equity and minimal assets reduce financial flexibility and borrowing capacity. This structural weakness weakens negotiating leverage with partners and lenders, increases the risk of distressed financings, and forces trade-offs between development programs if capital is scarce.

Persistent Cash BurnConsistent negative operating and free cash flow indicates ongoing funding needs to sustain clinical programs. Over time this creates dependency on dilutive equity or contingent partner funding, lengthens time to commercialization if raises are delayed, and elevates execution risk for clinical milestones.

Arch Biopartners News

Arch Biopartners publishes data linking cytokine IL-32 to inflammation, DKD

Arch Biopartners (ACHFF) announced that a scientific team led by Dr. Justin Chun at the University of Calgary...

3M ago

Arch Biopartners appoints Patrick Vink as chairman of the board

Arch Biopartners (ACHFF) announced the appointment of Dr. Patrick Vink as Chairman of the Company’s Board of Directors,...

4M ago

Arch granted ethics approval for St. Michaels participation in Phase II trial

Arch Biopartners (ACHFF) announced that the University Health Network Research Ethics Board has granted ethics approval for St....

5M ago

Arch Biopartners’ LSALT Peptide Study: A Promising Step in AKI Prevention

Arch Biopartners (($TSE:ARCH)) announced an update on their ongoing clinical study. Arch Biopartners is conducting a Phase 2...

7M ago

ARCH

ARCH FAQ

What was Arch Biopartners’s price range in the past 12 months?

Arch Biopartners lowest stock price was C$0.39 and its highest was C$1.95 in the past 12 months.

What is Arch Biopartners’s market cap?

Arch Biopartners’s market cap is C$30.23M.

When is Arch Biopartners’s upcoming earnings report date?

Arch Biopartners’s upcoming earnings report date is Jun 02, 2026 which is in 11 days.

How were Arch Biopartners’s earnings last quarter?

Currently, no data Available

Is Arch Biopartners overvalued?

According to Wall Street analysts Arch Biopartners’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Arch Biopartners pay dividends?

Arch Biopartners does not currently pay dividends.

What is Arch Biopartners’s EPS estimate?

Arch Biopartners’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Arch Biopartners have?

Arch Biopartners has 67,933,290 shares outstanding.

What happened to Arch Biopartners’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Arch Biopartners?

Currently, no hedge funds are holding shares in TSE:ARCH

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Arch Biopartners

Arch Biopartners Inc., a biotechnology company, develops technologies for medical or commercial impact. It focuses on developing its lead drug candidate Metablok to treat or prevent dipeptidase-1 mediated organ inflammation in the lungs, liver, or kidneys, which results in organ damage or failure, including in the case of sepsis and COVID-19. The company also develops AB569, a drug candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds. In addition, it develops Borg, a peptide-solid surface interface to inhibit biofilm formation and reduce corrosion; and MetaMx, which are synthetic molecules that target brain tumor initiating cells and invasive glioma cells. The company is based in Toronto, Canada.